Login Register Cart 0
Current Pharmaceutical Design

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Effects of CYP3A5 Genetic Polymorphisms on the Weight-adjusted through Concentration of Sirolimus in Renal Transplant Recipients: A Systematic Review and Meta-analysis

Author(s): Yoon-A Parkorcid of author, Juyeong Park, Jeong Yee*orcid of author and Hye Sun Gwak*

Volume 30, Issue 39, 2024

Published on: 21 August, 2024

Page: [3108 - 3115] Pages: 8

DOI: 10.2174/0113816128324199240730093415

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Background: Sirolimus, one of the immunosuppressive drugs administered to renal transplant recipients, is metabolized by cytochrome P450 (CYP) 3A5. Accordingly, CYP3A5 polymorphism is a genetic factor affecting sirolimus pharmacokinetics (PK). Therefore, we conducted a systematic review and meta-analysis on the association between sirolimus PK and CYP3A5*3 polymorphism.

Methods: We searched for studies published up to 13 June 2024 from PubMed, Embase, Cochrane Library, and Web of Science. We reviewed studies on the relationship between CYP3A5*3 polymorphism and weightadjusted trough concentration/dose (C0 /D) ratio and dosage of sirolimus in renal transplant recipients, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We evaluated mean differences (MDs) and 95% confidence intervals (CIs).

Results: A total of seven studies were included. The weight-adjusted C0 /D ratio of sirolimus was significantly higher in patients with the CYP3A5*3/*3 rather than CYP3A5*1/*1 or CYP3A5*1/*3 genotype (MD 95.27 ng/mL per mg/kg; 95% CI: 58.06, 132.47; I2 = 74%; p < 0.00001). Also, the weight-adjusted dosage of sirolimus was significantly lower in patients with the CYP3A5*3/*3 rather than CYP3A5*1/*1 or CYP3A5*1/*3 genotype (MD -2.60 × 10-3 mg/kg; 95% CI: -4.52, -0.69; I2 = 44%; p = 0.008).

Conclusion: Our meta-analysis showed a significant effect for the CYP3A5*3 genotype on weight-adjusted C0 /D ratio and dosage of sirolimus in adult renal transplant recipients.

Keywords: Cytochrome P450 3A5, pharmacogenomics, pharmacokinetics, renal transplantation, sirolimus, polymorphism.

« Previous Next »
[1]
Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331(6): 365-76.
[http://dx.doi.org/10.1056/NEJM199408113310606] [PMID: 7832839]
[2]
Chadban SJ, Ahn C, Axelrod DA, et al. Summary of the kidney disease: Improving global outcomes (KDIGO) clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation 2020; 104(4): 708-14.
[http://dx.doi.org/10.1097/TP.0000000000003137] [PMID: 32224812]
[3]
Oweira H, Ramouz A, Ghamarnejad O, et al. Risk factors of rejection in renal transplant recipients: A narrative review. J Clin Med 2022; 11(5): 1392.
[http://dx.doi.org/10.3390/jcm11051392] [PMID: 35268482]
[4]
Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351(26): 2715-29.
[http://dx.doi.org/10.1056/NEJMra033540] [PMID: 15616206]
[5]
Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353(9158): 1083-91.
[http://dx.doi.org/10.1016/S0140-6736(98)07493-5] [PMID: 10199367]
[6]
Bauer AC, Franco RF, Manfro RC. Immunosuppression in kidney transplantation: State of the art and current protocols. Curr Pharm Des 2020; 26(28): 3440-50.
[http://dx.doi.org/10.2174/1381612826666200521142448] [PMID: 32436821]
[7]
Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007; 67(3): 369-91.
[http://dx.doi.org/10.2165/00003495-200767030-00004] [PMID: 17335296]
[8]
Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. Lancet 2000; 356(9225): 194-202.
[http://dx.doi.org/10.1016/S0140-6736(00)02480-6] [PMID: 10963197]
[9]
Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997; 17(6): 1148-56.
[http://dx.doi.org/10.1002/j.1875-9114.1997.tb03080.x] [PMID: 9399599]
[10]
Panwar V, Singh A, Bhatt M, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther 2023; 8(1): 375.
[http://dx.doi.org/10.1038/s41392-023-01608-z] [PMID: 37779156]
[11]
Stenton SB, Partovi N, Ensom MHH. Sirolimus. Clin Pharmacokinet 2005; 44(8): 769-86.
[http://dx.doi.org/10.2165/00003088-200544080-00001] [PMID: 16029064]
[12]
Zimmerman KO, Wu H, Greenberg R, et al. Therapeutic drug monitoring, electronic health records, and pharmacokinetic modeling to evaluate sirolimus drug exposure-response relationships in renal transplant patients. Ther Drug Monit 2016; 38(5): 600-6.
[http://dx.doi.org/10.1097/FTD.0000000000000313] [PMID: 27259059]
[13]
Product Information: RAPAMUNE(R) oral solution, oral tablets, sirolimus oral solution, oral tablets. Wyeth Pharmaceuticals Inc. (per FDA), Philadelphia, PA. 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s059,021110s076lbl.pdf Accessed 15 June 2024.
[14]
Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin Transplant 2000; 14(2): 97-109.
[http://dx.doi.org/10.1034/j.1399-0012.2000.140201.x] [PMID: 10770413]
[15]
MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22(Suppl B): B101-121.
[http://dx.doi.org/10.1016/S0149-2918(00)89027-X]
[16]
Hardinger KL, Koch MJ, Brennan DC. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 2004; 24(9): 1159-76.
[http://dx.doi.org/10.1592/phco.24.13.1159.38094] [PMID: 15460177]
[17]
Holt DW, Johnston A. Monitoring immunosuppressive drugs. In: Hempel G, Ed. Drug Monitoring and Clinical Chemistry. Amsterdam, The Netherlands: Elsevier 2004; pp. 273-96.
[http://dx.doi.org/10.1016/S1567-7192(04)80012-3]
[18]
Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4- transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: Studies with sirolimus and midazolam. J Pharmacol Exp Ther 2004; 308(1): 143-55.
[http://dx.doi.org/10.1124/jpet.103.058065] [PMID: 14569063]
[19]
Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998; 285(3): 1104-12.
[PMID: 9618413]
[20]
Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: Part II. Clin Pharmacokinet 2009; 48(8): 489-516.
[http://dx.doi.org/10.2165/11317240-000000000-00000] [PMID: 19705921]
[21]
Tamashiro EY, Felipe CR, Genvigir FDV, et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. Drug Metab Pers Ther 2017; 32(2): 89-95.
[http://dx.doi.org/10.1515/dmpt-2016-0036] [PMID: 28593920]
[22]
Lolita L, Zheng M, Zhang X, et al. The genetic polymorphism of CYP3A4 rs2242480 is associated with sirolimus trough concentrations among adult renal transplant recipients. Curr Drug Metab 2020; 21(13): 1052-9.
[http://dx.doi.org/10.2174/1389200221999201027203401] [PMID: 33115392]
[23]
Bruckmueller H, Cascorbi I. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: What is our current understanding? Expert Opin Drug Metab Toxicol 2021; 17(4): 369-96.
[http://dx.doi.org/10.1080/17425255.2021.1876661] [PMID: 33459081]
[24]
Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006; 70(6): 1019-25.
[http://dx.doi.org/10.1038/sj.ki.5001649] [PMID: 16837925]
[25]
Shao S, Hu L, Han Z, et al. The effect of ABCB1 polymorphism on sirolimus in renal transplant recipients: A meta-analysis. Transl Androl Urol 2020; 9(2): 673-83.
[http://dx.doi.org/10.21037/tau.2020.03.42] [PMID: 32420174]
[26]
Wu MJ, Shu KH, Lian JD, Yang CR, Cheng CH, Chen CH. Impact of variability of sirolimus trough level on chronic allograft nephropathy. Transplant Proc 2008; 40(7): 2202-5.
[http://dx.doi.org/10.1016/j.transproceed.2008.07.029] [PMID: 18790192]
[27]
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372(71): n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[28]
The Newcastle-ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed 15 June 2024.
[29]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta- analysis. Stat Med 2002; 21(11): 1539-58.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[30]
Anglicheau D, Corre DL, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5(3): 595-603.
[http://dx.doi.org/10.1111/j.1600-6143.2005.00745.x] [PMID: 15707415]
[31]
Lee J, Huang H, Chen Y, Lu X. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2014; 35(3): 164-72.
[http://dx.doi.org/10.1002/bdd.1881] [PMID: 24285256]
[32]
Li Y, Yan L, Shi Y, Bai Y, Tang J, Wang L. CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients. Springerplus 2015; 4(1-6): 637.
[http://dx.doi.org/10.1186/s40064-015-1425-5] [PMID: 26543771]
[33]
Miao LY, Huang CR, Hou JQ, Qian MY. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2008; 29(1): 1-5.
[http://dx.doi.org/10.1002/bdd.577] [PMID: 17941052]
[34]
Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80(7): 977-84.
[http://dx.doi.org/10.1097/01.TP.0000174131.47469.D2] [PMID: 16249748]
[35]
Rodríguez-Jiménez C, García-Saiz M, Pérez-Tamajón L, Salido E, Torres A. Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. Drug Metab Pers Ther 2017; 32(1): 49-58.
[http://dx.doi.org/10.1515/dmpt-2016-0040] [PMID: 28245187]
[36]
Pączek L, Wyzgał J, Pączek L. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Ann Transplant 2012; 17(3): 36-44.
[http://dx.doi.org/10.12659/AOT.883456] [PMID: 23018254]
[37]
Khan AR, Raza A, Firasat S, Abid A. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: A systematic review and meta-analysis. Pharmacogenomics J 2020; 20(4): 553-62.
[http://dx.doi.org/10.1038/s41397-019-0144-7] [PMID: 31902947]
[38]
Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: A systematic review and meta-analysis of observational studies. Pharmacogenomics J 2015; 15(1): 38-48.
[http://dx.doi.org/10.1038/tpj.2014.38] [PMID: 25201288]
[39]
Zhu HJ, Yuan SH, Fang Y, Sun XZ, Kong H, Ge WH. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: A meta-analysis. Pharmacogenomics J 2011; 11(3): 237-46.
[http://dx.doi.org/10.1038/tpj.2010.26] [PMID: 20368718]
[40]
Zhang J, Dai Y, Liu Z, et al. Effect of CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of sirolimus in healthy chinese volunteers. Ther Drug Monit 2017; 39(4): 406-11.
[http://dx.doi.org/10.1097/FTD.0000000000000415] [PMID: 28700521]
[41]
Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81(2): 228-34.
[http://dx.doi.org/10.1038/sj.clpt.6100039] [PMID: 17192769]
[42]
Emoto C, Fukuda T, Venkatasubramanian R, Vinks AA. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: Insights from predictions with a physiologically-based pharmacokinetic model. Br J Clin Pharmacol 2015; 80(6): 1438-46.
[http://dx.doi.org/10.1111/bcp.12743] [PMID: 26256674]
[43]
Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Clin Pharmacokinet 2006; 45(11): 1135-48.
[http://dx.doi.org/10.2165/00003088-200645110-00007] [PMID: 17048977]
[44]
Lukas JC, Calvo R, Zografidis A, Ortega I, Suárez E. Simulation of sirolimus exposures and population variability immediately post renal transplantation: Importance of the patient’s CYP3A5 genotype in tailoring treatment. Biopharm Drug Dispos 2010; 31(2-3): 129-37.
[http://dx.doi.org/10.1002/bdd.697] [PMID: 20155737]
[45]
Khaled SK, Palmer JM, Herzog J, et al. Influence of absorption, distribution, metabolism, and excretion genomic variants on tacrolimus/sirolimus blood levels and graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016; 22(2): 268-76.
[http://dx.doi.org/10.1016/j.bbmt.2015.08.027] [PMID: 26325438]
[46]
Hakeam HA, Al-Jedai AH, Raza SM, Hamawi K. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. Ann Transplant 2008; 13(2): 46-53.
[PMID: 18566560]
[47]
Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Sirolimus modifies cholesterol homeostasis in hepatic cells: A potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation 2007; 84(8): 1029-36.
[http://dx.doi.org/10.1097/01.tp.0000286095.55685.e9] [PMID: 17989609]
[48]
Sam WJ, Chamberlain CE, Lee SJ, et al. Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. Transplantation 2012; 94(9): 971-7.
[http://dx.doi.org/10.1097/TP.0b013e31826b55e2] [PMID: 23073467]
[49]
Yang S, Jiang H, Li C, et al. Genomewide association study identifies a novel variant associated with tacrolimus trough concentration in Chinese renal transplant recipients. Clin Transl Sci 2022; 15(11): 2640-51.
[http://dx.doi.org/10.1111/cts.13388] [PMID: 35977080]
[50]
Liu J, Feng D, Kan X, et al. Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation. Pharmacogenomics 2021; 22(14): 903-12.
[http://dx.doi.org/10.2217/pgs-2021-0083] [PMID: 34523354]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 75
Html icon 2
Find your institution